Release date: 14 September 2015
Promoter – Financial Intermediary
IMPERIAL INNOVATIONS GROUP PLCLocation
Description
Development and commercialisation of research from leading UK universities. The research and development (R&D) will be particularly focused on state-of-the-art technology.
Objectives
This project concerns investments in the life science sector, which accounts for well over half of the promoter's overall investment programme. It covers activities ranging from pre-seed and seed financing and proof-of-concept studies to the financing of pre-clinical and clinical trials of its portfolio companies. They include, for example, investments into early stages such as target validation and hit-to-lead development, lead optimisation and toxicology studies as well as Phase I and Phase II clinical trials. The larger investments targeted at more mature portfolio companies are based on a milestone/tranche basis that matches the companies' needs for cash with the agreed milestone.
Sector(s)
Proposed EIB finance (Approximate amount)
EUR 70 million (GBP 50 million)
Total cost (Approximate amount)
EUR 154 million (GBP 110 million)
Environmental aspects
R&D activities included in the project will not materially change current R&D practice and will be carried out within existing facilities, making use of existing laboratories, pilot plants, clinical centres etc. An environmental impact assessment (EIA) by a competent authority according to Directive 2011/92/EU should not be required.
Procurement
The promoter is a private company not operating in the utilities sector and is thus not covered by EU directives on procurement.
Status
Signed - 13/07/2015
Disclaimer
Before financing approval by the Board of Directors, and before loan signature, projects are under appraisal and negotiation. The information and data provided on this page are therefore indicative.
They are provided for transparency purposes only and cannot be considered to represent official EIB policy (see also the Explanatory notes).